Whole cell screen based identification of spiropiperidines with potent antitubercular properties

• Published in: Bioorganic & Medicinal Chemistry Letters (ISSN: 0960-894X), vol. 25, num. 16, p. 3234-3245
• Oxford: Elsevier, 2015

Whole cell based screens to identify hits against Mycobacterium tuberculosis (Mtb), carried out under replicating and non-replicating (NRP) conditions, resulted in the identification of multiple, novel but structurally related spiropiperidines with potent antitubercular properties. These compounds could be further classified into three classes namely 3-(3-aryl-1,2,4-oxadiazol-5-yl)-1'-alkylspiro[indene-1,4'-piperidine] (abbr. spiroindenes), 4-(3-aryl-1,2,4-oxadiazol-5-yl)-1'-alkylspiro[chromene-2,4'-piperidine] (abbr. spirochromenes) and 1'-benzylspiro[indole-1,4'-piperidin]-2(1H)-one (abbr. spiroindolones). Spiroindenes showed >= 4 log(10) kill (at 2-12 mu M) on replicating Mtb, but were moderately active under non replicating conditions. Whole genome sequencing efforts of spiroindene resistant mutants resulted in the identification of I292L mutation in MmpL3 (Mycobacterial membrane protein Large), required for the assembly of mycolic acid into the cell wall core of Mtb. MIC modulation studies demonstrated that the mutants were cross-resistant to spirochromenes but not to spiroindolones. This Letter describes lead identification efforts to improve potency while reducing the lipophilicity and hERG liabilities of spiroindenes. Additionally, as deduced from the SAR studies, we provide insights regarding the new chemical opportunities that the spiroindolones can offer to the TB drug discovery initiatives. (C) 2015 Elsevier Ltd. All rights reserved.

Keywords: Whole cell screen ; ss18b ; Antimycobacterial ; Non-replicating phase ; Hypoxic conditions ; MmpL3

Reference

• EPFL-ARTICLE-212051
• doi:10.1016/j.bmcl.2015.05.087
• View record in Web of Science

Record created on 2015-09-28, modified on 2017-05-12